| Date | Title | Description | Source |
| 03.04.2024 | Inventiva annonce le dépôt de son Document d’Enregistrement ... | Daix (France), Long Island City (New York, United States), le 3 avril 2024 – Inventiva (Euronext Par... | einpresswi... |
| 03.04.2024 | Inventiva announces filing of its 2023 Universal Registratio... | Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris... | einpresswi... |
| 22.03.2024 | Inventiva annonce la date de publication et de présentation ... | Daix (France), Long Island City (New York, Etats-Unis), le 22 mars 2024 – Inventiva (Euronext Paris ... | einpresswi... |
| 22.03.2024 | Inventiva announces the schedule of publication and presenta... | Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Pari... | einpresswi... |
| 18.03.2024 | Inventiva annonce les résultats positifs de l’essai clinique... | LEGEND a atteint son critère principal d’efficacité en réduisant de manière significative le taux d’... | einpresswi... |
| 18.03.2024 | Inventiva announces positive results from the Phase II, LEGE... | LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lani... | einpresswi... |
| 13.03.2024 | Inventiva annonce la présentation des résultats de son étude... | Daix (France), Long Island City (New York, États-Unis), le 13 mars 2024 – Inventiva (Euronext Paris ... | einpresswi... |
| 13.03.2024 | Inventiva to present the results of LEGEND Phase IIa combina... | Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Pari... | einpresswi... |
| 13.03.2024 | Inventiva to present the results of LEGEND Phase IIa combina... | - | globenewsw... |
| 07.03.2024 | Inventiva announces that screening in the NATiV3, Phase III,... | - | globenewsw... |
| 15.02.2024 | Inventiva reports preliminary 2023 fiscal year financial Inf... | Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022
Cash and cas... | einpresswi... |
| 10.01.2024 | Inventiva draws down the second tranche of €25 million under... | Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical ... | einpresswi... |
| 21.11.2023 | Inventiva reports 2023 Third Quarter Financial Information¹ | Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million2, and long-term dep... | einpresswi... |
| 21.11.2023 | Inventiva publie ses informations financières du 3ème trimes... | Trésorerie et équivalents de trésorerie à 43,8 millions d’euros, dépôt à court terme à 0,03 million ... | einpresswi... |
| 24.06.2023 | Inventiva annonce la présentation d’un abstract scientifique... | /EIN News/ -- Daix (France), Long Island City (New York, United States), le 24 juin 2023 – Inventiva... | einpresswi... |
| 24.06.2023 | Inventiva announces the presentation of a scientific abstrac... | /EIN News/ -- Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (... | einpresswi... |
| 07.06.2023 | Inventiva annonce cinq présentations scientifiques lors de l... | Cinq présentations par poster démontrant :
La corrélation entre l'amélioration de la stéatose hépati... | einpresswi... |
| 25.05.2023 | DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'A... | /EIN News/ -- Daix, le 25 mai 2023
En application de l'article 241-2 du Règlement Général de l’Autor... | einpresswi... |
| 25.05.2023 | Description of the Share Repurchase Program Authorised by th... | /EIN News/ -- Daix, 25 May 2023
Pursuant to Article 241-2 of the AMF General Regulations (Règlement ... | einpresswi... |
| 04.01.2023 | Inventiva annonce des changements au développement clinique ... | Les changements proposés devraient être bénéfiques pour le programme clinique de lanifibranor en réd... | einpresswi... |
| 04.01.2023 | Inventiva announces changes to the clinical development of l... | Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the ... | einpresswi... |
| 12.12.2022 | Inventiva draws down €25 million tranche under Finance Contr... | - | globenewsw... |
| 12.12.2022 | Inventiva draws down €25 million tranche under Finance Contr... | Inventiva intends to use the proceeds to fund part of the pivotal Phase III clinical trial evaluatin... | einpresswi... |
| 12.12.2022 | Inventiva annonce le tirage de la première tranche de 25 mil... | Inventiva utilisera le produit de ce tirage pour financer une partie de l'étude clinique pivot de Ph... | einpresswi... |
| 31.10.2022 | Inventiva provides an update on the development of cedirogan... | Daix (France), Long Island City (New York, United States), October 31, 2022 – Inventiva (Euronext Pa... | globenewsw... |
| 21.10.2022 | Inventiva announces a scientific presentation at the AASLD T... | /EIN News/ -- Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiv... | einpresswi... |
| 21.10.2022 | Inventiva annonce la présentation d’un abstract scientifique... | /EIN News/ -- Daix (France), Long Island City (New York, Etats-Unis), le 21 octobre 2021 Daix (Franc... | einpresswi... |
| 21.10.2022 | Inventiva announces a scientific presentation at the AASLD T... | Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Pa... | globenewsw... |
| 22.09.2022 | Inventiva reports its 2022 first-half financial results and ... | Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 20... | globenewsw... |
| 21.09.2022 | Inventiva and Sino Biopharm announce licensing and collabora... | Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and ... | globenewsw... |
| 21.09.2022 | Inventiva and Sino Biopharm announce licensing and collabora... | Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and ... | einpresswi... |
| 07.09.2022 | Inventiva announces the schedule of publication and presenta... | Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (Euronext P... | globenewsw... |
| 28.07.2022 | Inventiva Reports 2022 First-Half Financial Information¹ | Cash position2 at €87.2 m as of June 30, 2022
Revenues of €0.1 m in H1 2022
Inventiva entered into a... | globenewsw... |
| 21.07.2022 | Half-Year Review of Inventiva’s Liquidity Contract with Kepl... | Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (Euronext Paris... | globenewsw... |
| 07.07.2022 | Inventiva announces the screening of the first patient in LE... | The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor i... | globenewsw... |
| 04.07.2022 | Update on Inventiva's cash position and on the finance docum... | Inventiva successfully raised approximately €14.6 million through a combination of its ATM Program f... | globenewsw... |
| 16.06.2022 | Inventiva to host a webcast with Key Opinion Leaders followi... | Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH ... | globenewsw... |
| 09.06.2022 | Inventiva announces three scientific presentations at the EA... | Three poster presentations showing
the beneficial effects of lanifibranor on markers of cardiometabo... | globenewsw... |
| 03.06.2022 | Inventiva announces the presentation of a scientific abstrac... | Daix (France), Long Island City (New York, United States), June 3, 2022 – Inventiva (Euronext Paris ... | globenewsw... |
| 23.05.2022 | Inventiva announces participation at several investors confe... | Daix (France), Long Island City (New York, United States), May 23, 2022 – Inventiva (Euronext Paris ... | globenewsw... |
| 20.05.2022 | Results of the votes of the Combined Shareholders’ Meeting o... | Daix (France), Long Island City (New York, United States), May 20, 2022 – Inventiva (Euronext Paris ... | globenewsw... |
| 16.05.2022 | Inventiva secures a €50 million credit facility from the Eur... | This credit facility is intended to support the progress and expansion of Inventiva’s pipeline
The c... | globenewsw... |
| 16.05.2022 | Inventiva reports 2022 First Quarter Financial Information a... | Cash position2 at €80.5m as of March 31, 2022
The Group did not generate any revenue in Q1 2022
Sign... | globenewsw... |
| 28.04.2022 | Statement of total voting rights and shares forming the comp... | Article R. 22-10-23 of the French Commercial Code
Market : Euronext Paris
ISIN code / Mnemo : FR0013... | globenewsw... |
| 28.04.2022 | Combined General Meeting of May 19, 2022 - Availability of t... | Daix (France), Long Island City (New York, United States), April 28, 2022 – Inventiva (Euronext Pari... | globenewsw... |
| 07.04.2022 | Inventiva announces the presentation of a scientific abstrac... | Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (Euronext Paris... | globenewsw... |
| 11.03.2022 | Inventiva announces filing of its 2021 Universal Registratio... | Daix (France), Long Island City (New York, United States), March 11, 2022 – Inventiva (Euronext Pari... | globenewsw... |
| 08.03.2022 | Inventiva announces that its IND application for the Phase I... | FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed
The initiation of ... | globenewsw... |
| 07.03.2022 | Inventiva reports its 2021 Full-Year Results: key milestones... | Initiation of the NATiV3 Phase III clinical trial with lanifibranor in NASH
Receipt of a €4 m milest... | globenewsw... |
| 07.03.2022 | Inventiva publie ses résultats annuels 2021 : Avancées majeu... | Lancement de l’étude clinique de Phase III NATiV3 avec lanifibranor dans la NASH
Réception d’un pai... | globenewsw... |
| 01.03.2022 | Inventiva announces participation at several conferences in ... | Daix (France), Long Island City (New York, United States), March 1, 2022 – Inventiva (Euronext Paris... | globenewsw... |
| 28.02.2022 | Inventiva announces the schedule of publication and presenta... | Daix (France), Long Island City (New York, United States), February 28, 2022 – Inventiva (Euronext P... | globenewsw... |
| 14.02.2022 | Inventiva reports cash position and revenues for Full-Year 2... | Cash position2 at €95.4m as of December 31, 2021, compared to €105.7m on September 30, 2021, and €11... | globenewsw... |
| 01.02.2022 | Inventiva receives a 4 million milestone payment from AbbVi... | Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Pa... | marketscre... |
| 01.02.2022 | Inventiva receives a EUR4 million milestone payment from Abb... | Daix (France), Long Island City (New York, United States) - Inventiva (Euronext Paris and Nasdaq: IV... | marketscre... |
| 31.01.2022 | Inventiva receives a €4 million milestone payment from AbbVi... | Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Pa... | globenewsw... |
| 20.01.2022 | Inventiva announces participation at several conferences in ... | Daix (France), Long Island City (New York, United States), January 20, 2022 – Inventiva (Euronext Pa... | globenewsw... |
| 14.01.2022 | Half-Year Review of Inventiva’s Liquidity Contract with Kepl... | Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq:... | globenewsw... |
| 16.12.2021 | Inventiva to present at the 40th Annual J.P. Morgan Healthca... | Daix (France), Long Island City (New York), December 16, 2021 – Inventiva (Euronext Paris and Nasdaq... | globenewsw... |
| 06.12.2021 | Inventiva announces positive results of clinical thorough QT... | Trial conducted in 217 patients to evaluate the potential effect of lanifibranor on the QT/QTc inter... | globenewsw... |
| 10.11.2021 | Inventiva reports 2021 Third Quarter Financial Information | Cash and cash equivalents at €105.7m as of September 30, 2021
Revenues of €0.2m for the first nine m... | globenewsw... |
| 03.11.2021 | Inventiva to host a webcast with Key Opinion Leaders from th... | Presentation of five scientific abstracts selected for poster presentations at the AASLD The Liver M... | globenewsw... |
| 29.10.2021 | Inventiva announces participation at several conferences in ... | Daix (France), Long Island City (New York, United States), November 29, 2021 – Inventiva (Euronext P... | marketscre... |
| 29.10.2021 | Inventiva announces participation at several conferences in ... | Daix (France), Long Island City (New York, United States), November 29, 2021 – Inventiva (Euronext P... | globenewsw... |
| 29.10.2021 | Inventiva announces participation at several investor confer... | Daix (France), Long Island City (New York, United States), November 29, 2021 - Inventiva (Euronext P... | marketscre... |
| 27.10.2021 | Inventiva announces the design of LEGEND, a Phase IIa combin... | The LEGEND trial is a proof-of-concept Phase IIa clinical trial to evaluate the safety and efficacy ... | marketscre... |
| 27.10.2021 | Inventiva announces the design of LEGEND, a Phase IIa combin... | The LEGEND trial is a proof-of-concept Phase IIa clinical trial to evaluate the safety and efficacy ... | globenewsw... |
| 27.10.2021 | Inventiva announces the design of LEGEND, a Phase IIa combin... | Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 ... | marketscre... |
| 21.10.2021 | The New England Journal of Medicine publishes the results of... | In the Phase IIb NATIVE, lanifibranor met both the primary and key secondary endpoints, including NA... | marketscre... |
| 20.10.2021 | The New England Journal of Medicine publishes the results of... | In the Phase IIb NATIVE, lanifibranor met both the primary and key secondary endpoints, including NA... | globenewsw... |
| 18.10.2021 | Inventiva announces the presentation of five scientific abst... | Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on k... | globenewsw... |
| 18.10.2021 | Inventiva : announces the presentation of five scientific ab... | Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on k... | marketscre... |
| 28.09.2021 | Inventiva : announces participation at several investor conf... | Daix (France), Long Island City (New York, United States), September 28, 2021 – Inventiva (Euronext ... | marketscre... |
| 20.09.2021 | Inventiva : H1 2021 financial results and corporate update | PRESS RELEASE
Inventiva reports 2021 first half financial results and
provides a corporate update
Ca... | marketscre... |
| 20.09.2021 | Inventiva : H1 2021 Interim Financial Report | INVENTIVA S.A.
joint-stockcompany (société anonyme) with a share capital of 386,593.61euros Register... | marketscre... |
| 20.09.2021 | Inventiva : reports 2021 first half financial results and pr... | Cash and cash equivalents at €93.6 m as of June 30, 2021 compared to €105.7 m1 as of December 31, 20... | marketscre... |
| 08.09.2021 | Inventiva : announces the initiation of its pivotal Phase II... | Activation of first clinical sites and start of patient screening
The two-part NATiV3 Phase III clin... | marketscre... |
| 30.08.2021 | Inventiva : announces participation at several investor conf... | Daix (France), August 30, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopha... | marketscre... |
| 03.08.2021 | Inventiva : announces the implementation of an At-The-Market... | Daix (France), August 2, 2021 (GLOBE NEWSWIRE) – Inventiva S.A. (NASDAQ: IVA – EURONEXT PARIS: IVA) ... | marketscre... |
| 09.06.2021 | INVENTIVA
Inventiva announces three scientific presentation... | Two oral presentations showing
the beneficial effects of lanifibranor on cardiovascular risk biomark... | marketscre... |
| 04.03.2021 | 2020 Full-Year Results: Major advances in NASH and significa... | ► Publication of positive topline results from the NATIVE Phase IIb clinical trial evaluating lanifi... | globenewsw... |
| 04.03.2021 | Résultats annuels 2020 : Avancées majeures dans la NASH et v... | ► Publication des principaux résultats positifs de l'étude clinique de Phase IIb NATIVE évaluant lan... | globenewsw... |
| 23.02.2021 | Inventiva’s 2020 Full-Year Financial Results Presentation | Daix (France), February 23, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biop... | globenewsw... |
| 11.02.2021 | Full-Year 2020: Cash position and revenues | Cash position2 at €113.0m as of December 31, 2020 compared to €124.6 million at September 30, 2020 a... | globenewsw... |
| 11.02.2021 | Exercice 2020 : Position de trésorerie et chiffre d’affaires... | Position de trésorerie2 à 113,0 M€ au 31 décembre 2020 contre 124,6 M€ au 30 septembre 2020 et 35,8 ... | globenewsw... |
| 19.02.2019 | French biotech Inventiva's lead drug stumbles in system... | France’s Inventiva (Euronext: $IVA) has suffered its first big setback following its public... | endpts.com... |
| 19.04.2018 | Inventiva Pharma Raises €35.5M in Funding | Inventiva Pharma (Euronext Paris: IVA), a Paris, France-based biopharmaceutical company, raised €35.... | finsmes.co... |
| 13.04.2018 | Inventiva raises €36M to prep for phase 3 NASH trial
W h i ... | Inventiva has raised €36 million ($44 million) to gear up for a phase 3 trial of pan-PPAR activator ... | fiercebiot... |
| 13.04.2018 | Inventiva raises €36M to prep for phase 3 NASH trial | Inventiva has raised €36 million ($44 million) to gear up for a phase 3 trial of pan-PPAR activator ... | fiercebiot... |
| 15.02.2017 | Inventiva completes €48M IPO to fund phase 2b NASH trial | Inventiva has raised €48 million ($51 million) through an IPO in Paris, France. The offering gives t... | fiercebiot... |
